Strategy Selection of Antiplatelet Therapy for Ischemic Stroke in terms of the Ethnic Differences between Easterners and Westerners

doi:10.3969/j.issn.1673-5765.2018.05.016

Abstract

Abstract:

Stroke has become a global disease burden. Antiplatelet therapy is a necessary method for secondary prevention of ischemic stroke. However, there are differences between Easterners and Westerners on features of disease, which may lead to different antiplatelet therapy. Through the analysis of difference in disease characteristics, risk of recurrence and bleeding, and variability of platelet response, this review will explore the appropriate antiplatelet therapy for ischemic stroke patients in Asia.

Key words: Stroke; Antiplatelet drugs; Secondary prevention; Genetic polymorphism

摘要：

全球卒中的疾病负担沉重，抗血小板治疗是缺血性卒中二级预防的必要手段，然而东西方人群的疾病特点存在差异，可能对抗血小板治疗的选择产生影响。本综述从卒中发病特点、患者复发和出血风险差异以及抗血小板治疗反应多样性等多角度出发，探讨适合亚洲人群的缺血性卒中抗血小板治疗方案。

关键词: 卒中; 抗血小板药物; 二级预防; 基因多态性

Wang Yi-Long. Strategy Selection of Antiplatelet Therapy for Ischemic Stroke in terms of the Ethnic Differences between Easterners and Westerners[J]. Chinese Journal of Stroke, 2018, 13(05): 494-499.

王伊龙. 从东西方种族差异看缺血性卒中抗血小板治疗策略选择[J]. 中国卒中杂志, 2018, 13(05): 494-499.

References

[1] TSAI C F，THOMAS B，SUDLOW C L.

Epidemiology of stroke and its subtypes in Chinese

vs white populations：a systematic review[J].

Neurology，2013，81（3）：264-272.

[2] TSAI C F，ANDERSON N，THOMAS B，et al.

Risk factors for ischemic stroke and its subtypes

in Chinese vs. Caucasians：Systematic review and

meta-analysis[J]. Int J Stroke，2015，10（4）：485-493.

[3] FEIGIN V L，FOROUZANFAR M H，

KRISHNAMURTHI R，et al. Global and regional

burden of stroke during 1990-2010：findings from

the Global Burden of Disease Study 2010[J]. Lancet，

2014，383（9913）：245-254.

[4] WANG Y，CUI L，JI X，et al. The China

National Stroke Registry for patients with acute

cerebrovascular events：design，rationale，and

baseline patient characteristics [J]. Int J stroke，2011，

6（4）：355-361.

[5] WANG Y，ZHAO X，JIANG Y，et al. Prevalence，

knowledge，and treatment of transient ischemic

attacks in China[J]. Neurology，2015，84（23）：

2354-2361.

[6] WANG Y，MINEMATSU K，WONG K S，et al.

Ticagrelor in Acute Stroke or Transient Ischemic

Attack in Asian Patients：From the SOCRATES Trial

（Acute Stroke or Transient Ischemic Attack Treated

With Aspirin or Ticagrelor and Patient Outcomes）[J].

Stroke，2017，48（1）：167-173.

[7] KIM B J，KIM J S. Ischemic stroke subtype

classification：an Asian viewpoint[J]. J Stroke，2014，

16（1）：8-17.

[8] HOLMSTEDT C A，TURAN T N，CHIMOWITZ M

I. Atherosclerotic intracranial arterial stenosis：risk

factors，diagnosis，and treatment[J]. Lancet Neurol，

2013，12（11）：1106-1114.

[9] SATO S，TOYODA K，MATSUOKA H，et

al. Isolated anterior cerebral artery territory

infarction：dissection as an etiological mechanism[J].

Cerebrovasc Dis，2010，29（2）：170-177.

[10] GO A S，MOZAFFARIAN D，ROGER V L，et al.

Heart disease and stroke statistics--2014 update：a

report from the American Heart Association[J/OL].

Circulation，2014，129（3）：e28-e292. https：//doi.

org/10.1161/01.cir.0000441139.02102.80.

[11] ROTHWELL P M，GILES M F，CHANDRATHEVA

A，et al. Effect of urgent treatment of transient

ischaemic attack and minor stroke on early recurrent

stroke（EXPRESS study）：a prospective populationbased

sequential comparison[J]. Lancet，2007，370

（9596）：1432-1442.

[12] ROTHWELL P M，ALGRA A，CHEN Z，et

al. Effects of aspirin on risk and severity of early

recurrent stroke after transient ischaemic attack

and ischaemic stroke：time-course analysis of

randomised trials[J]. Lancet，2016，388（10042）：

365-375.

[13] NELSON S，CLOONAN L，KANAKIS A S，et

al. Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic

Stroke[J]. J Stroke Cerebrovasc Dis，2016，25（10）：

2519-2525.

[14] JOHNSTON S C，AMARENCO P. Ticagrelor

versus Aspirin in Acute Stroke or Transient Ischemic

Attack[J]. N Engl J Med，2016，375（14）：1395.

[15] KENNEDY J，HILL M D，RYCKBORST K J，et

al. Fast assessment of stroke and transient ischaemic

attack to prevent early recurrence（FASTER）：a

randomised controlled pilot trial[J]. Lancet Neurol，

2007，6（11）：961-969.

[16] WANG Y，PAN Y，ZHAO X，et al. Clopidogrel With

Aspirin in Acute Minor Stroke or Transient Ischemic

Attack（CHANCE）Trial：One-Year Outcomes[J].

Circulation，2015，132（1）：40-46.

[17] LIU L，WONG K S，LENG X，et al. Dual

antiplatelet therapy in stroke and ICAS：Subgroup

analysis of CHANCE[J]. Neurology，2015，85（13）：

1154-1162.

[18] PAN Y，JING J，LI H，et al. Abnormal glucose

regulation increases stroke risk in minor ischemic

stroke or TIA[J]. Neurology，2016，87（15）：1551-

1556.

[19] ZHOU Y，PAN Y，WU Y，et al. Effect of Estimated

Glomerular Filtration Rate Decline on the Efficacy

and Safety of Clopidogrel With Aspirin in Minor

Stroke or Transient Ischemic Attack：CHANCE

Substudy（Clopidogrel in High-Risk Patients With

Acute Nondisabling Cerebrovascular Events）[J].

Stroke，2016，47（11）：2791-2796.

[20] JOHNSTON S C，EASTON J D，FARRANT M，

et al. Platelet-oriented inhibition in new TIA and

minor ischemic stroke（POINT）trial：rationale and

design[J]. Int J Stroke，2013，8（6）：479-483.

[21] HUGHES S. TARDIS：Triple Antiplatelet Therapy

No Benefit in Stroke，TIA[C]. International Stroke

Conference（ISC）2017，Medscape，2017.

[22] LEVINE G N，JEONG YH，GOTO S，et al. Expert

consensus document：World Heart Federation expert

consensus statement on antiplatelet therapy in East

Asian patients with ACS or undergoing PCI[J]. Nat

Rev Cardiol，2014，11（10）：597-606.

[23] WANG Y，CHEN W，LIN Y，et al. Safety and

Feasibility of Combination of Ticagrelor and Aspirin

in Patients With Minor Stroke or TIA：Interim

Analyses of the Platelet Reactivity in Acute Stroke

or Transient Ischemic Attack（PRINCE）Trial[C].

International Stroke Conference（ISC）2017，

Medscape，2017.

[24] PAN Y，JING J，CHEN W，et al. Risks and benefits

of clopidogrel-aspirin in minor stroke or TIA：Time course analysis of CHANCE[J]. Neurology，2017，88

（20）：1906-1911.

[25] WONG K S，WANG Y，LENG X，et al. Early dual

versus mono antiplatelet therapy for acute noncardioembolic

ischemic stroke or transient ischemic

attack：an updated systematic review and metaanalysis[

J]. Circulation，2013，128（15）：1656-1666.

[26] CHEN S，SHEN Q，TANG Y，et al. Efficacy and

safety of adding clopidogrel to aspirin on stroke

prevention among high vascular risk patients：a

meta-analysis of randomized controlled trials[J/

OL]. PLoS One，2014，9（8）：e104402. https：//doi.

org/10.1371/journal.pone.0104402.

[27] 中华医学会神经病学分会，中华医学会神经病学分

会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺

血发作二级预防指南2014[J]. 中华神经科杂志，2015，

48（4）：258-273.

[28] MAO L，JIAN C，CHANGZHI L，et al.

Cytochrome CYP2C19 polymorphism and risk of

adverse clinical events in clopidogrel-treated patients：

a meta-analysis based on 23，035 subjects[J]. Arch

Cardiovasc Dis，2013，106（10）：517-527.

[29] WANG Y，ZHAO X，LIN J，et al. Association

Between CYP2C19 Loss-of-Function Allele Status

and Efficacy of Clopidogrel for Risk Reduction

Among Patients With Minor Stroke or Transient

Ischemic Attack[J]. JAMA，2016，316（1）：70-78.[30] PAN Y，CHEN W，XU Y，et al. Genetic

Polymorphisms and Clopidogrel Efficacy for

Acute Ischemic Stroke or Transient Ischemic

Attack：A Systematic Review and Meta-Analysis[J].

Circulation，2017，135（1）：21-33.

[31] VARENHORST C，JAMES S，ERLINGE D，et

al. Genetic variation of CYP2C19 affects both

pharmacokinetic and pharmacodynamic responses

to clopidogrel but not prasugrel in aspirin-treated

patients with coronary artery disease[J]. Eur Heart J，

2009，30（14）：1744-1752.

[32] WALLENTIN L，JAMES S，STOREY R F，et al.

Effect of CYP2C19 and ABCB1 single nucleotide

polymorphisms on outcomes of treatment with

ticagrelor versus clopidogrel for acute coronary

syndromes：a genetic substudy of the PLATO trial[J].

Lancet，2010，376（9749）：1320-1328.

[33] JOHNSTON S C，AMARENCO P，ALBERS G W，

et al. Ticagrelor versus Aspirin in Acute Stroke or

Transient Ischemic Attack[J]. N Engl J Med，2016，

375（14）：35-43.

[34] JAUCH E C，SAVER J L，ADAMS H P JR，et al.

Guidelines for the early management of patients with

acute ischemic stroke：a guideline for healthcare

professionals from the American Heart Association/

American Stroke Association[J]. Stroke，2013，44

（3）：870-947.